zolbetuximab
astellas
[]
primary results spotlight study:
zolbetuximab + mfolfox6 as first-line treatment for patients with claudin-18.2+ / her2 unresectable or metastatic gastric or gej adenocarcinoma #gi23 pfs: 10.6 vs 8.6 m os: 18.2 vs 15.5 m 
MD, Associate Professor, Medical Oncologist. Deputy Editor at @OfOncological. #breastcancer #colorectalcancer #lungcancer #precisionmedicine #HealthForAll